Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Myelomonocytic Leukemia; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Polycythemia Vera; Recurrent Adult Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia Interventions: Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Other: Placebo; Drug: Topotecan Hydrochloride; Drug: Veliparib Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified September 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials